Sidewinder, a San Diego-based biotechnology company, has completed a $137 million Series B funding round to advance its antibody-drug conjugate (ADC) platform. The seven-employee startup attracted investment from blue-chip investors for its bispecific approach to cancer treatment.
The company is developing ADCs that aim to deliver the therapeutic power of traditional antibody-drug conjugates while reducing associated toxicities. This approach represents a significant advancement in cancer drug development, as current ADCs often face limitations due to severe side effects that can limit dosing and efficacy.